Iovance Biotherapeutics (Mfg)

Philadelphia, PA
Cell Therapy
29 confirmed programs · 11 sponsors · Last scored 2026-03-15
60.5
Signal Score
○ FDA Inspections ✓ Clinical Trials (29) ○ SEC Filings ○ Press

Quick Facts: Iovance Biotherapeutics (Mfg)

Signal Score
60.5/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Philadelphia, PA
Modalities
Cell Therapy
Active CGT Programs
29 confirmed from ClinicalTrials.gov across 11 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs 29
Sponsors11
ModalitiesCell Therapy
29 active programs across 11 sponsors
Modalities: Cell Therapy
19 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07192900 Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease PHASE1 Recruiting
NCT07288073 TIL Therapy in cSCC and MCC PHASE2 Recruiting
NCT07288203 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in... PHASE2 Recruiting
NCT05639972 E7 T-cell Receptor (TCR) -T Cell Induction Therapy for... PHASE1/PHASE2 Recruiting
NCT06940739 A Study to Investigate the Safety and Efficacy of IOV-3001 in... PHASE1/PHASE2 Recruiting
NCT06481592 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in... PHASE2 Recruiting
NCT06151847 Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide... PHASE2 Unknown
NCT05727904 Study to Investigate Lifileucel Regimen Plus Pembrolizumab... PHASE3 Recruiting
NCT05686226 E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV)... PHASE2 Recruiting
NCT05607095 A Study of LN-144 or LN-145 in People With Advanced Uveal... PHASE1 Recruiting
View all 29 programs →
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 68.0
Parent company: Iovance Biotherapeutics
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of Iovance Biotherapeutics
SEC FilingsParent: Iovance Biotherapeutics
Parent company: Iovance Biotherapeutics
Financial assessment: 68.0/100
Capacity 53.0
1 CGT manufacturing site: Philadelphia, PA
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: Philadelphia, PA
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
1 CGT manufacturing site: Philadelphia, PA
Modalities: Cell Therapy
Capacity assessment: 53.0/100

Clinical Activity 29 studies

NCT07192900 Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease PHASE1 Recruiting NCT07288073 TIL Therapy in cSCC and MCC PHASE2 Recruiting NCT07288203 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With... PHASE2 Recruiting NCT05639972 E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally... PHASE1/PHASE2 Recruiting NCT06940739 A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With... PHASE1/PHASE2 Recruiting NCT06481592 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With... PHASE2 Recruiting NCT06151847 Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion... PHASE2 Unknown NCT05727904 Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With... PHASE3 Recruiting NCT05686226 E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers PHASE2 Recruiting NCT05607095 A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma,... PHASE1 Recruiting NCT05483491 KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer PHASE1 Recruiting NCT05361174 A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in... PHASE1/PHASE2 Recruiting NCT05176470 Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for... PHASE1 Active Not Recruiting NCT04614103 Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer PHASE2 Recruiting NCT04155710 Study of Autologous Peripheral Blood Lymphocytes in the Treatment of... PHASE1 Completed NCT04111510 Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated... PHASE2 Completed NCT04052334 Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent... PHASE1 Completed NCT03935347 Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in... PHASE2 Withdrawn NCT03645928 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors PHASE2 Recruiting NCT03610490 Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With... PHASE2 Terminated
+ 9 more studies
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Cell Therapy CDMOs →